SecBot SecBot
SECBOTREPLAY Home › Report › BNTX

BNTX · BioNTech and BMS announced interim Phase 2 data from the ROSETTA…

BioNTech SE · 6-K filed Jun 1, 2026 at 07:59 ET

At the news

BULLISHIMPACT 6/10

6-K filed Jun 1, 2026 at 07:59 ET

BioNTech and BMS announced interim Phase 2 data from the ROSETTA Lung-02 trial of pumitamig (PD-L1xVEGF-A bispecific) plus chemotherapy in first-line non-small cell lung cancer. The data showed a confirmed objective response rate of 57.1% in non-squamous and 68.4% in squamous NSCLC, with a 100% disease control rate, and a manageable safety profile. This is a positive clinical update for a key pipeline asset, but the data are early-stage (Phase 2, n=40) and the stock impact is likely modest given the pre-revenue nature of the company.

  • Interim Phase 2 data from ROSETTA Lung-02 trial of pumitamig (BNT327/BMS-986545) plus chemotherapy in first-line advanced NSCLC.
  • Confirmed objective response rate (cORR) of 57.1% in non-squamous and 68.4% in squamous NSCLC; disease control rate (DCR) of 100%.
  • At the lower dose, cORR was 63.6% for non-squamous and 72.7% for squamous subtypes.
  • cORR by PD-L1 expression: 47.6% (TPS <1%), 77.8% (TPS 1-49%), 100% (TPS ≥50%).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access